Year: 2022
BERGENBIO ANNOUNCES PUBLICATION IN CELL REPORTS MEDICINE JOURNAL INDICATING EFFICACY OF BEMCENTINIB IN STK11/LKB1 LUNG CANCER POPULATION
March 17, 2022
The article identifies the key role of AXL inhibition in restoring response to immune checkpoint…
Read MoreBERGENBIO ASA: RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2021
February 16, 2022
Bergen, Norway, 16 February 2022 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors for…
Read MoreBerGenBio and Oslo University Hospital Announce the AXL Inhibitor Bemcentinib will be Studied in the EU Funded EU-SolidAct trial in Hospitalised COVID-19 Patients
January 27, 2022
Bergen/Oslo, Norway 27 January 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read MoreBerGenBIO APPOINTS ANDERS TULLGREN as Chairman of Board
January 6, 2022
Bergen, Norway, 6 January 2022 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…
Read More
